Potent and highly selective histamine H3 receptor agonist (pEC50 = 9.74) that displays 300-fold selectivity over the H4 receptor (pKi values are 9.07 and 6.61 respectively). Does not bind to H1 or H2 receptors at concentrations up to 10 μM. .
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 321.01. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.12 mL||15.58 mL||31.15 mL|
|5 mM||0.62 mL||3.12 mL||6.23 mL|
|10 mM||0.31 mL||1.56 mL||3.12 mL|
|50 mM||0.06 mL||0.31 mL||0.62 mL|
References are publications that support the products' biological activity.
Kitbunnadaj et al (2004) Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H3 receptor agonist. J.Med.Chem. 47 2414 PMID: 15115383
If you know of a relevant reference for Immethridine dihydrobromide, please let us know.
View Related Products by Product Action
Keywords: Immethridine dihydrobromide, supplier, Potent, H3, agonists, selective, over, H4, Receptors, Histamine, histaminergic, Histamine, H3, Receptors, Histamine, H3, Receptors, Tocris Bioscience
Citations for Immethridine dihydrobromide
Citations are publications that use Tocris products.
Currently there are no citations for Immethridine dihydrobromide. Do you know of a great paper that uses Immethridine dihydrobromide from Tocris? If so please let us know.
Immethridine dihydrobromide Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.